Literature DB >> 23627580

Chronic angle-closure glaucoma related to paroxetine treatment.

M A Sierra-Rodriguez1, F Saenz-Frances, E Santos-Bueso, J Garcia-Feijoo, J C Gonzelez-Romero.   

Abstract

PURPOSE: To present a unique case of a 33-year-old woman using paroxetine who presented with acute unilateral visual loss due to chronic angle-closure glaucoma.
METHODS: Case report.
RESULTS: A 33-year-old women who had been under paroxetine treatment for the past four months presented at the emergency room due to a sudden loss of visual acuity (VA) in the left eye (LE). Narrow anterior chamber was detected. Intraocular pressure (IOP) was 29 mmHg right eye (RE) and 42 mm Hg LE. A fundus exam revealed a cup-to-disc ratio of 0.9-1 for the LE and of 0.1-0.2 for the RE. Paroxetine treatment was suspended, and after 48 h IOP was 10 mm Hg in both eyes (BE). ND-YAG laser iridotomy was performed in BE. In the subsequent visit, IOP was 25 mm Hg in the RE and 41 mm Hg in the LE; on her own initiative the patient had resumed paroxetine treatment. After requesting the patient again to stop taking the anti-depressant, IOP was 10 mm Hg in BE in the next exam 48 h later.
CONCLUSIONS: As far as we are aware, there are no other reports of chronic angle-closure glaucoma related to the use of paroxetine. We thus consider that, before initiating treatment with this drug, patients should be informed of its potential ocular risks and they should be subjected to an ophthalmologic examination before its use is authorized.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627580     DOI: 10.3109/08820538.2013.771193

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  2 in total

1.  Evaluation of the effects of duloxetine treatment on anterior segment parameters by optical coherence tomography.

Authors:  Murat A Özer; İlker F Sarı; Hakan Koç; Nurçe Ç Yavuz; Serkan Özen; Fazıl Kulaklı
Journal:  Int Ophthalmol       Date:  2022-07-07       Impact factor: 2.031

Review 2.  A review of systemic medications that may modulate the risk of glaucoma.

Authors:  Annie Wu; Anthony P Khawaja; Louis R Pasquale; Joshua D Stein
Journal:  Eye (Lond)       Date:  2019-10-08       Impact factor: 3.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.